Rhythm Biosciences Doubles ColoSTAT Test Network and Expands Clinician Access Program

Rhythm Biosciences Ltd. ( (AU:RHY) ) just unveiled an announcement.

Rhythm Biosciences has accelerated the commercial roll-out of its ColoSTAT colorectal cancer blood test in Australia through its partnership with 4Cyte Pathology, more than doubling activated commercial collection centres to seventy-eight across the ACT, New South Wales, Queensland and Victoria, including regional towns. This broader footprint, supported by online location tools, is intended to significantly improve test accessibility for symptomatic patients and underpin rising test volumes as clinician awareness grows.

The ColoSTAT Access Program, which provides a structured pathway for early commercial use while collecting real-world clinical data, has now reached ten participating clinician sites spanning general practitioners and specialist surgeons in three states. The enrolment of Clinical Advisory Board chair Professor Finlay Macrae AO adds further clinical leadership and credibility, with management reporting early test orders and re-orders as evidence of growing momentum and adoption for ColoSTAT in routine colorectal cancer assessment.

The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.

More about Rhythm Biosciences Ltd.

Rhythm Biosciences Ltd is an Australian cancer diagnostics company focused on predictive and transformative technologies, with its lead product ColoSTAT designed as a blood-based aid for the triage and diagnosis of patients with symptoms of colorectal and bowel cancer. The company is targeting both major urban and regional healthcare markets through pathology partnerships and clinician-led access programs to drive early adoption and real-world evidence generation.

Average Trading Volume: 950,677

Technical Sentiment Signal: Buy

Current Market Cap: A$63.51M

For detailed information about RHY stock, go to TipRanks’ Stock Analysis page.